Hospital Groups Urge HRSA to Take ‘Immediate Enforcement Action’ Against J&J’s Contested 340B Rebate Proposal

Two major hospital groups urged the government to take enforcement action against J&J's 340B rebate proposal.
Two major hospital advocacy groups are urging the federal agency that oversees the 340B program to “take immediate enforcement action” [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Analysis Finds Growing Private Equity, Corporate Investments in 340B; Firm Conducting Study Fails to Mention Its Own PE Funding

A new Berkeley Research Group issue brief looked at trends in 340B investments.
The 340B program’s growth in recent decades has helped it attract a growing number of corporate and private equity investments, [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »
Industry Insights Logo

Preparing for a Neutral 340B Claims Clearinghouse

SPONSORED CONTENT

On June 18th, RxParadigm hosted a webinar to discuss the pressing need for a 340B clearinghouse. Legislative changes at both state and federal levels for the 340B program could be imminent, requiring all stakeholders to adapt to new standards

Read More »

State Contract Pharmacy Lawsuit Weekly Roundup: Judge Calls Astra Subpoenas ‘Overly Broad,’ Mo. Officials Push to Dismiss Lawsuit 

Key orders and briefs were filed this week in state contract pharmacy litigation in Arkansas, Missouri and West Virginia.
Editor’s Note: With 340B-related litigation heating up in several states following the enactment of new contract pharmacy access laws this [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Two More Drugmakers Partially Exempt Missouri Providers from 340B Contract Pharmacy Restrictions

Sanofi joins at least eight other drugmakers that have partially or fully loosened their 340B contract pharmacy restrictions in Missouri.
Drugmakers Sanofi and Sumitoma Pharma America (SMPA) each announced they are partially exempting Missouri-based providers from their contract pharmacy restrictions [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

340B INDUSTRY LEADER SPOTLIGHT

Christina Breckenridge, Senior Director of Client Success, RxStrategies

Christina Breckenridge

Q: Where did you grow up?

Kansas City, Missouri

Q: Where did you go to college/graduate school?

For undergraduate work, I went to school in Springfield, Missouri, at what was then Southwest Missouri State University and is now Missouri State University. I earned 2 graduate degrees in Kansas City, Missouri, at the University of Missouri-Kansas City.

Q:

Read More »

J&J’s Contested 340B Rebate Proposal Would Further Limit Contract Pharmacies, Give Drugmaker More Control of Program, Attorneys Say

J&J's plans to convert certain 340B discounts to a rebate model would reshape the 340B program.
Johnson & Johnson’s (J&J’s) proposed 340B rebate model, which has not received government approval, would give the drugmaker significantly more [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Missouri’s 340B Contract Pharmacy Access Law Takes Effect Tomorrow as More Drugmakers Restore Discounts, Others Sue State

Missouri's law prohibiting drugmaker 340B contract pharmacy restrictions takes effect Aug. 28.
Missouri’s new law prohibiting drugmaker 340B contract pharmacy restrictions takes effect tomorrow, and the drug industry has responded with more [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Kedrion Posts 340B Refund Notice; Mylan Issue NDC Changes

Kedrion was one of two drugmakers to issue recent notices to covered entities on a federal government agency website.
Drugmaker Kedrion Biopharma has posted a refund notice to 340B providers, and Mylan notified covered entities of National Drug Code [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Column: Unilateral Imposition of Rebate Model for the 340B Program is a Non-Starter

Ted Slafsky, publisher and CEO of 340B Report, writes about a major drugmaker's proposed 340B rebate model.
If things were not difficult enough already for 340B providers, hospitals woke up on Friday morning to an announcement that [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »